Teva Pharmaceutical Industries (TEVA) Receivables (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Receivables across 18 years of filings, most recently posting $3.4 billion for Q1 2026.

• Quarterly Receivables changed 0.27% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (changed 0.27% YoY) and the FY2025 annual result came in at $3.7 billion, up 21.25% from the prior year.
• Receivables declined to $3.4 billion in Q1 2026, from $3.7 billion in the prior quarter.
• Over five years, Receivables peaked at $4.5 billion in Q2 2022 and troughed at $3.1 billion in Q4 2024.
• A 5-year average of $3.6 billion and a median of $3.5 billion in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables decreased 20.85% — and 2025, when it rose 21.25%.
• Tracing TEVA's Receivables over 5 years: stood at $3.7 billion in 2022, then slipped by 7.79% to $3.4 billion in 2023, then declined by 10.24% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025, then retreated by 8.52% to $3.4 billion in 2026.
• Business Quant data shows TEVA's Receivables at $3.4 billion in Q1 2026, $3.7 billion in Q4 2025, and $3.8 billion in Q3 2025.